All In Biotech

Drug Trial Radar · NCT04480853

Safety and Efficacy Study of Fingolimod in Taiwanese Adults (≥ 20years) With Relapsing Remitting Multiple Sclerosis

A 12-month, Prospective, Multi-center Post-authorization Commitment (PAC) Study Monitoring Safety in Adult Patients With Relapsing-remitting Multiple Sclerosis Newly Initiated on Gilenya (Fingolimod) in Taiwan (SPRING)

Last checked: Nov 20, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

14

Actual

Start

Oct 12, 2020

Primary completion

Oct 15, 2026

Study completion Nov 15, 2026

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Jul 21, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 20 years, up to 100 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to describe the safety profile of fingolimod in the Taiwanese multiple sclerosis population. This study aims to collect the safety data in patients newly initiated on fingolimod for one year.

Conditions

  • Multiple Sclerosis

Interventions

  • FingolimodDrug

    Fingolimod 0.5 mg QD, oral

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Adverse Events of Special Interest(AESI)Time frame: First Dose Observation on the first day of taking findolimod
  2. Number of Adverse Events of Special Interest (AESI)Time frame: Baseline up to 12 months

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Novartis Investigative Site

    Kaohsiung City, Taiwan

  • Novartis Investigative Site

    Taichung, Taiwan

  • Novartis Investigative Site

    Taipei, Taiwan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.